News & Updates
Filter by Specialty:
Can losartan delay the progression of AD?
In individuals with clinically diagnosed mild-to-moderate Alzheimer’s disease (AD), treatment with the angiotensin II receptor blocker (ARB) losartan for 12 months did not reduce the rate of brain atrophy, findings from the phase II RADAR* trial suggest.
Can losartan delay the progression of AD?
13 Dec 2021
Cutting first-day dexamethasone dose not recommended for breast cancer patients on anthracycline
In breast cancer patients treated with anthracycline-containing regimens, reducing the first-day dose of dexamethasone does not yield significant gastrointestinal benefit and is not recommended for nausea management, a recent study has found.
Cutting first-day dexamethasone dose not recommended for breast cancer patients on anthracycline
11 Dec 2021
Sildenafil efficacy, safety sustained regardless of delivery method
Sildenafil orally disintegrating strips (ODS) are just as effective and safe as the conventional tablet formulation for the treatment of erectile dysfunction (ED), a Thai study suggests.
Sildenafil efficacy, safety sustained regardless of delivery method
11 Dec 2021
Low-dose aspirin does not stave off dementia
A daily 100 mg dose of aspirin for 7 years did not reduce the risk of dementia in individuals with diabetes and no history of cardiovascular disease (CVD), according to results of the ASCEND* study presented at AHA 2021.
Low-dose aspirin does not stave off dementia
10 Dec 2021
Guselkumab safe, well tolerated in patients with psoriatic arthritis
Treatment with the monoclonal antibody targeting interleukin [IL]-23p19 guselkumab 100 mg, given either every 4 (Q4W) or 8 weeks (Q8W), is well tolerated in patients with psoriatic arthritis (PsA), with no new safety concerns through 1 year, according to pooled results of the DISCOVER-1 and DISCOVER-2 phase III trials.
